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Abstract
Molecular diagnostic testing of individuals with congenital sensorineural hearing loss typically begins with DNA sequencing
of the GJB2 gene. If the cause of the hearing loss is not identified in GJB2, additional testing can be ordered. However, the
step-wise analysis of several genes often results in a protracted diagnostic process. The more comprehensive Hereditary
Hearing Loss Arrayed Primer Extension microarray enables analysis of 198 mutations across eight genes (GJB2, GJB6, GJB3,
GJA1, SLC26A4, SLC26A5, MTRNR1 and MTTS1) in a single test. To evaluate the added diagnostic value of this microarray for
our ethnically diverse patient population, we tested 144 individuals with congenital sensorineural hearing loss who were
negative for biallelic GJB2 or GJB6 mutations. The array successfully detected all GJB2 changes previously identified in the
study group, confirming excellent assay performance. Additional mutations were identified in the SLC26A4, SLC26A5 and
MTRNR1 genes of 12/144 individuals (8.3%), four of whom (2.8%) had genotypes consistent with pathogenicity. These
results suggest that the current format of this microarray falls short of adding diagnostic value beyond the customary
testing of GJB2, perhaps reflecting the array’s limitations on the number of mutations included for each gene, but more
likely resulting from unknown genetic contributors to this phenotype. We conclude that mutations in other hearing loss
associated genes should be incorporated in the array as knowledge of the etiology of hearing loss evolves. Such future
modification of the flexible configuration of the Hereditary Hearing Loss Arrayed Primer Extension microarray would
improve its impact as a diagnostic tool.
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Introduction
Hearing loss is a common birth defect and the most prevalent
sensory disorder affecting newborns in developed nations. The
estimated incidence of permanent hearing loss at birth, defined in
the U.S. as a sensorineural loss of 35 dB or more, is nearly one per
500 newborns [1]. The causes of hearing loss may be genetic,
environmental or multifactorial. However, at least 50% of
prelingual hearing loss in industrialized countries is of genetic
origin [2]. Hearing loss can be non-syndromic when present in
isolation (,70%) or syndromic when accompanied by additional
clinical features (,30%) [3]. It can be inherited as a recessive,
dominant,X-linked or mitochondrial trait, with autosomal recessive
inheritance comprising approximately 80% of non-syndromic
sensorineural hearing loss (NSNHL). Different mutations within
thesame gene canresultineitherdominant orrecessiveinheritance,
further increasing the genetic complexity of this condition. As many
as 300 human genes are thought to be involved in the process of
hearing [4] and to date, more than 100 mapped or characterized
loci have been implicated in NSNHL (Hereditary Hearing Loss
home page: http://webh01.ua.ac.be/hhh/).
Current recommendations for molecular diagnostic testing of
patients with congenital hearing loss advise to first test the GJB2
gene that encodes the gap junction protein connexin 26. If the
molecular basis of the hearing loss was not identified, this test may
be followed by analyses of other genes, such as the del(GJB6-
D13S1830) deletion in GJB6 that encodes connexin 30 [2]. These
two genes are adjacently located at the DFNB1 locus of
chromosome 13q12, where mutations have been detected in as
many as 50% of patients with autosomal recessive NSNHL [5].
However, a retrospective study in a large North American cohort
reported that only 24.3% of patients diagnosed with NSNHL
carried GJB2 sequence changes [6]. Furthermore, biallelic GJB2
variants were identified in just 11.2% of cases and the del(GJB6-
D13S1830) deletion in GJB6 was present in only 2.8% of
individuals monoallelic for GJB2 mutations. These results suggest
that genes in loci other than DFNB1 may play a considerable role
in the etiology of NSNHL.
In order to provide a faster, more comprehensive and cost-
effective assay for NSNHL mutations, the HHL APEX (Hered-
itary Hearing Loss Arrayed Primer Extension) microarray was
developed [7]. The APEX array comprises a panel of 198
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GJB6, GJB3, GJA1, SLC26A4 and SLC26A5) and two mitochon-
drial genes (MTRNR1 and MTTS1). APEX array technology
facilitates the simultaneous analysis of multiple mutations through
hybridization of fragmented template DNA to specifically designed
primers, followed by single nucleotide extension at the site of each
putative mutation [8,9]. We wished to determine whether the
HHL APEX microarray provides added diagnostic value beyond
the standard testing of GJB2. Consequently, we studied 144
individuals with NSNHL in whom only one recessive GJB2
mutation, one del(GJB6-D13S1830) deletion or no mutations had
been identified by clinical genotyping. Our goal was to not only
evaluate the APEX array as a diagnostic tool but also to further
elucidate the contribution of the genes on the array to the
development of congenital NSNHL.
Materials and Methods
Study subjects
This study was conducted at Stanford University with 144
participating individuals, mostly children, diagnosed with congen-
ital NSNHL. All participants were probands, and none of their
family members were enrolled in this study. Participants were
either recruited at the California Ear Institute or at Stanford
University under IRB approval with informed consent. Prior to
enrollment, all participants had been tested for mutations in the
GJB2 gene by DNA sequencing as part of their routine clinical
care. Some had received additional testing by PCR for the
del(GJB6-D13S1830) deletion. To assess the added clinical
diagnostic value of the HHL APEX microarray in its present
configuration, this study included individuals for whom only one
recessive GJB2 mutation, one del(GJB6-D13S1830) deletion, or no
mutations had previously been identified. Patients with a clear
environmental cause for their hearing loss (such as significant noise
exposure, a history of trauma, ototoxic medications, intrauterine
infection, tumor or other known condition that affects hearing)
were excluded. Although an environmental contribution cannot
be entirely ruled out in any individual with hearing loss, it is
unlikely to be a significant factor in any of our probands.
Individuals with unequivocal syndromic hearing loss were also
excluded from this study.
Microarray Design
The APEX microarray (Asper Biotech) includes 198 mutations
selected from six nuclear genes (GJB2, GJB6, GJB3, GJA1,
SLC26A4 and SLC26A5) and two mitochondrial genes (MTRNR1
and MTTS1); a detailed list of sequence variants is provided in
Table S1. These genes were selected because they have been
implicated in sensorineural hearing loss [7]. The mutation list
encompasses single nucleotide changes as well as insertions and
deletions, including the large del(GJB6-D13S1830) deletion which
truncates the GJB6 gene. For each of the 198 mutations on the
array, 25 bp oligonucleotides were constructed in both the sense
and antisense directions, based on the wild-type consensus
sequence for each gene (www.ncbi.nlm.nih.gov/Genbank/).
These were spotted in duplicate onto each microarray slide.
Most oligonucleotides were designed to be extended by 1 bp,
directly at the site of the mutation, allowing accurate detection of
the nucleotide change. However, for those deletions and
insertions for which this extension resulted in the same nucleotide
as was present in the wild-type DNA, optimal discrimination was
achieved by oligonucleotides extending further into the deletion
or insertion.
Genomic template preparation
Genomic DNA was extracted from saliva using the OrageneH
DNA self-collection kit (DNA Genotek, Inc) according to the
manufacturer’s protocol, or from peripheral blood following
standard procedures. Genomic regions of interest were first PCR
amplified and purified and then enzymatically treated with uracil
N-glycosylase and shrimp alkaline phosphatase to concurrently
fragment the DNA and inactivate unincorporated dinucleotide
triphosphates.
APEX reactions and analysis
APEX was performed as previously described [7]. Briefly,
fragmented genomic template DNA was denatured, mixed with
Thermo Sequenase DNA Polymerase (USB Corporation) and
fluorescently labeled dideoxynucleotides before being applied to
microarray slides for a 20 minute isothermic APEX reaction. After
washing the slides, duplicate fluorescent signals for both
complementary DNA strands were detected and recorded using
a Genorama Quattroimager (Asper Biotech), thus producing four
analytical data points corresponding to each mutation position.
This approach reduces the likelihood of false positive signals while
ensuring a clear distinction between homozygous and heterozy-
gous sequence changes.
Results
We sought to assess whether the HHL APEX array provides
additional value as a diagnostic tool and to determine the
frequencies of mutations included on the array in our participants
with congenital NSNHL. If the subject’s mutations are included
on the APEX array, detection of two mutations would be expected
when the hearing loss displays a recessive pattern of inheritance;
these two mutations may either be homozygous and located at a
single mutation site, or compound heterozygous with mutations at
two different positions within a gene. If the patient has dominant
sensorineural hearing loss, then a single dominant mutation would
be expected. Representative APEX array results for two study
subjects with congenital NSNHL are presented in Fig 1. A
heterozygous W24X (71G.A) mutation was identified in the
GJB2 gene of a single patient (42 CEI-P, Fig 1A). Fig 1B depicts
the homoplasmic mutation 1555A.G detected in the mitochon-
drial MTRNR1 gene of a second patient (45 MP-P). Both
mutations were identified in the forward and reverse sequence
directions. No appreciable differences in APEX signal quality were
observed when comparing assay results for templates amplified
from genomic DNA derived from saliva versus results for
templates derived from blood (data not shown).
The sequence variants detected by the microarray, including
those few changes classified as benign by the Connexin-Deafness
Homepage (http://davinci.crg.es/deafness/), are summarized in
Table S1. Sequence changes were identified in 35.4% (51/144) of
subjects; 8.3% (12/144) carried previously undetected mutations
in the SLC26A4, SLC26A5 and/or MTRNR1 genes (Table 1).
Mutations and changes of, as yet, unknown clinical significance in
the pendrin gene (SLC26A4) were identified in nine subjects and
encompassed six heterozygous, one homozygous and two
compound heterozygous sequence changes. Of the six individuals
in whom heterozygous SLC26A4 mutations were discovered, three
carried heterozygous sequence changes in other genes. One
patient carried the benign R127H variant in GJB2 as well as the
L597S variant in SLC26A4; two others carried splice variant IVS2-
2A.G (of unknown clinical significance) in the prestin gene
(SLC26A5) with either the F335L or the V609G mutation in
SLC26A4.
Hearing Loss APEX Microarray
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changes in the SLC26A4 gene, the APEX array also detected
sequence variants in the SLC26A5 and MTRNR1 genes of three
others. Two carried the IVS2-2A.G splice variant in the
SLC26A5 gene. A third individual was homoplasmic for the
1555A.G mutation of the MTRNR1 gene that encodes the 12S-
rRNA in mitochondria (Fig 1). This individual also carried the
V37I mutation in the GJB2 gene. In total, the APEX array
identified potentially pathogenic genotypes in only four patients
(2.8%, 4/144): three were either homozygous or compound
heterozygous for sequence changes in the nuclear SLC26A4 gene
and one was homoplasmic for the 1555A.G substitution in the
mitochondrial MTRNR1 gene. Changes in GJB3, GJA1, and
MTTS1 were not identified in any subjects.
Discussion
The implementation of universal newborn hearing screening
across the U.S. has resulted in early identification of hearing loss
with benefits to language, social, and cognitive development [10].
The majority of affected children (,70%) will have no other
clinical manifestations, which precludes a diagnosis of the
underlying etiology by clinical examination. Molecular diagnostic
testing, typically starting with DNA sequence analysis of the GJB2
gene, is frequently conducted to identify the underlying cause of
the hearing loss, enabling accurate genetic counseling and guiding
management and treatment. However, depending on the
population studied, mutations in GJB2 only provide a definitive
explanation in up to half of the individuals with NSNHL. When a
molecular cause is not identified by testing the GJB2 gene, analysis
of additional genes is frequently pursued, based on clinical and
family history as well as cost considerations. Such testing is usually
Figure 1. APEX detection of the W24X (71G.A) mutation in GJB2
and the 1555A.Gm u t a t i o ni nMTRNR1.A) W24X in GJB2. Row 1. Wild-
type genotype for nucleotide position 71 in the GJB2 gene. In the sense
direction (S) the wild-type G allele is detected, and in the antisense (AS)
direction the complementary C allele is identified. Row 2. Heterozygous for
W24X. S: the wild-type G allele and the mutant A allele are both present. AS:
the wild-type C allele and the mutant T allele are detected. Row 3. Negative
control. B) 1555A.Gi nMTRNR1. Row 1. Wild-type genotype for nucleotide
position 1555 in the MTRNR1 gene. The wild-type A allele is identified in S,
and the complementary T allele is detected in AS. Row 2. Homoplasmic for
1555A.G. S: the mutant G allele is present. AS: the complementary mutant
C allele is detected. Row 3. Negative control.
doi:10.1371/journal.pone.0011804.g001
Table 1. Genotypes detected by APEX in 144 congenitally hearing impaired individuals with one or no previously identified GJB2
or GJB6 mutations.
Homozygous (n) Compound Heterozygous (n) Heterozygous (n) Multiple Sequence Variants (n)
GJB2; V27I*/V27I* 5 GJB2; M34T#/333-334delAA 1 GJB2; G12V 1 GJB2; V27I*/V27I/E114G 2
(GJB2; V27I*)/SLC26A4; 919-2A.G/919-2A.G 1 SLC26A4; IVS1-2A.G**/L236P 1 GJB2; 35delG 2 GJB2; V27I*/V37I 1
SLC26A4; N324Y/V609G 1 GJB2; W24X 1 GJB2; V27I*/E114G* 1
GJB2; V27I* 13 (GJB2; V37I)/MTRNR1; 1555A.G
{ 1
GJB2; M34T 2 GJB2; R127H*/SLC26A4; L597S** 1
GJB2; V37I 3 SLC26A4; F335L/SLC26A5; IVS2-2A.G** 1
GJB2; R127H* 2 SLC26A4; V609G/SLC26A5; IVS2-2A.G** 1
GJB2; S139N 1
GJB2; R165W 1
GJB2; W172X 1
GJB2; I203T* 2
SLC26A4; G209V 1
SLC26A4; L597S** 1
SLC26A4; V609G 1
SLC26A5; IVS2-2A.G** 2
6 3 Total 34 8
*Benign Variant.
**Unknown clinical significance.
{Homoplasmic.
#Pathogenic with reduced penetrance; of unclear clinical significance at the time of study, which is why this patient was included. [30].
doi:10.1371/journal.pone.0011804.t001
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if successful, can span years. The HHL APEX array was
developed to provide added value to the diagnostic process by
testing eight different genes in a single test, thus drastically
shortening the time to molecular diagnosis. The array includes all
mutations reported for each included gene at the time of
development of the assay. However, novel mutations in several
genes, including GJB2 and SLC26A4, continue to be discovered
and are spread throughout the genes without true hot-spots. Lack
of identification of mutations on the HHL array, therefore, does
not necessarily exclude a gene as the cause of the hearing loss,
illustrating an intrinsic disadvantage of any assay that does not
examine the entire gene sequence. Ideally, clinical diagnostic
testing with an APEX-based array would cover all known variants
for the included genes and would not require follow-up sequencing
in the majority of cases. However, until we have a more complete
understanding of the mutation spectrum in individual genes,
targeted diagnostic sequencing would be a follow-up tool to
screening with the APEX assay, for individuals in whom a single
pathogenic mutation was found in a gene on the array.
Our study group was comprised of individuals in whom only
one recessive GJB2 mutation, one del(GJB6-D13S1830) deletion
or no mutations had previously been identified by clinical
diagnostic testing. Given that GJB2 and GJB6 mutations are
included as part of the APEX panel, a subset of the subjects was
known to carry mutant alleles that should be confirmed by APEX
testing. Of the 51 patient genotypes detected by the array, 42
included sequence changes in GJB2. The array results for these 42
individuals were consistent with the previous molecular diagnostic
findings (data not shown), thus confirming the reported 100%
sensitivity and reliability of the HHL APEX assay [7]. Mutations
in the connexin gene family of gap junction proteins represent
approximately half of the array and encompass sequence changes
in the GJB2 (connexin 26), GJB6 (connexin 30), GJB3 (connexin
31) and GJA1 (connexin 43) genes. Mutations in GJB2 are the
most common known cause of autosomal recessive NSNHL in
many populations [11], while the frequency of deletions in GJB6
appears much more population-dependent [6]. Mutations in GJB3
and GJA1 were also chosen for inclusion on the microarray, based
on early studies linking changes in these genes with NSNHL
[12,13]. Sequence changes in GJB3 have been identified in
individuals with hearing loss from several populations [14], but
they are rare and their pathogenicity remains controversial. In
addition, the mutations identified in GJA1 that were associated
with sensorineural hearing loss may actually be located in a
pseudogene of the connexin 43-encoding GJA1 gene, on
chromosome 5 [15]. Considering that the APEX array did not
detect a single GJB3 or GJA1 variant in any of our study subjects,
and without further evidence implicating the involvement of these
two genes in NSNHL, inclusion of GJB3 or GJA1 in future
versions of the APEX array may not be warranted.
In addition to connexin mutations, the array includes sequence
variants in the SLC26A4 and SLC26A5 genes, two members of the
SLC26 family of anion transporters. SLC26A5 has been implicated
in non-syndromic SNHL [16] whereas SLC26A4 gene mutations
are associated with both autosomal recessive non-syndromic
SNHL (DFNB4) and Pendred syndrome [17,18]. Pendred
syndrome is a relatively common form of syndromic deafness that
often appears non-syndromic during childhood. The actual
incidence is difficult to ascertain due to the late onset and
incomplete penetrance of the characteristic euthyroid goiter [19].
Furthermore, without performing computed tomography or
magnetic resonance imaging an enlarged vestibular aqueduct
(EVA) or Mondini dysplasia, which are associated with Pendred
syndrome but not pathognomonic, are not observable. Consider-
ing the phenotypic variability among patients with SLC26A4
mutations and the difficulty of diagnosing Pendred syndrome, the
frequency of sensorineural hearing loss resulting from DFNB4/
Pendred syndrome may be underestimated [20]. At least one
SLC26A4 variant was detected by the APEX array in nine subjects.
Unfortunately, temporal bone imaging results were not available
on these patients. The array identified one SLC26A4 homozygous
(919-2A.G/919-2A.G) and two compound heterozygous geno-
types (N324Y/V609G and IVS1-2A.G/L236P). Of note,
whereas L236P is a frequently occurring SLC26A4 mutation,
accounting for 16% of Pendred disease-causing alleles [21], IVS1-
2A.G is a rare splice variant, the clinical significance of which has
yet to be established. In silico predictions, as well as discordant
segregation with EVA in an affected fraternal twin pair suggest
that this sequence change may not actually affect gene function or
expression [22,23]. Six individuals carried a single mutant
SLC26A4 allele, either alone or in combination with a mutant
allele at a second gene locus. Although some studies do correlate
hearing loss with non-syndromic EVA in patients carrying a single
SLC26A4 mutation [22,23], the assumed mode of inheritance is
autosomal recessive. The most plausible explanation for not
detecting a second SLC26A4 mutation in these individuals is that
the mutation was not included on the APEX panel. This is not
necessarily due to the method, however: even with full SLC26A4
gene sequencing, only a single mutation is identified in a third of
multiplex families with Pendred syndrome (http://www.ncbi.nlm.
nih.gov/sites/GeneTests/?db=GeneTests). Four individuals were
heterozygous for the IVS2-2A.G variant in SLC26A5. Similar to
IVS1-2A.Gi nSLC26A4, its clinical significance is unknown.
Expected to result in the skipping of exon 3 during RNA
processing, it has been found at the same frequency in individuals
with hearing loss and in a control group and pathogenicity seems
now unlikely [24,25]. Therefore, this gene would likely be
excluded from future versions of the APEX assay. Finally, a
single, homoplasmic mitochondrial mutation (1555A.G in the
MTRNR1 gene) was identified. Both mitochondrial genes on the
array represent mutation hot-spot regions associated with NSHL
[26]. The 1555A.G mutation predisposes affected individuals to
irreversible hearing loss upon treatment with aminoglycosides.
Recently, two high-throughput resequencing arrays for muta-
tions in SNHL-associated genes were developed by research
groups from Harvard and from Cincinnati [27]. These Affymetrix-
based arrays encompass a total of 13 genes that were selected
based on published mutation frequencies, recessive inheritance
patterns and severity of genetic impact on patient outcome. The
HHL APEX array and the Affymetrix resequencing arrays both
incorporate the GJB2, GJB6, SLC26A4 and SLC26A5 genes.
Overall, however, the resequencing arrays represent a broader
spectrum of SNHL genes, with more genes associated with
syndromic hearing loss. In particular, three genes implicated in
Type 1 Usher syndrome (CDH23, MYO7A and USH1C), while
selected for the resequencing arrays, were not incorporated in the
HHL APEX array; a separate APEX array for this group of
disorders was already available when the HHL APEX array was
originally designed [28]. In addition to compositional differences,
the HHL APEX array and the Affymetrix resequencing arrays
employ different assay methodologies. The HHL APEX array
focuses specifically on the detection of previously reported hearing
loss mutations whereas the Affymetrix resequencing arrays allow
for the discovery of new mutations. However, resequencing arrays
have reduced ability to detect small deletions and insertions, which
constitute ,24% of disease-causing mutations in the Human Gene
Mutation Database [27]. The HHL APEX array was specifically
Hearing Loss APEX Microarray
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addition, the Harvard and Cincinnati groups both reported a high
false-positive rate (,70%) among identified variants, thus
requiring confirmatory sequencing which is time-consuming and
adds cost [27].
Mutations in the MYO15A, OTOF, TMC1 and other genes have
emerged as being among the more prevalent nonsyndromic
hearing loss mutations, worldwide [3]. These mutations were not
included on the APEX microarray because, at the time of its
design, only limited data were available regarding the role of these
genes in hearing loss. Furthermore, the information available in
the literature was restricted to small groups encompassing specific
geographic populations [29]. As future versions of the APEX
microarray are developed, consideration will be given to
incorporating these genes in the APEX platform.
Although APEX array technology provides a sensitive and
reliable platform for mutation detection, our investigation of the
HHL APEX microarray as a relatively comprehensive assay for
our multi-ethnic patient population revealed a lack of additional
diagnostic value beyond standard molecular diagnostic testing of
GJB2. Of 144 probands negative for biallelic GJB2 and/or GJB6
mutations, the HHL array identified previously unidentified
sequence changes in only 12 individuals (8.3%) among whom
four potentially pathogenic genotypes were found (2.8%). These
results suggest the existence of previously unreported hearing loss
mutations in the eight genes comprising the HHL APEX panel,
and, more importantly, mutations in pathogenic loci not currently
included. Since the APEX panel must necessarily be limited to a
finite number of genes and sequence variants, the present array
configuration may also not accurately represent the most frequent
hearing loss alleles in a given test population. Further research will
be required to characterize allele frequencies in distinct popula-
tions, and to identify new mutations in the hundreds of genes
comprising the molecular hearing apparatus. The APEX micro-
array does offer a flexible platform that can be easily modified to
alter mutation composition and/or to increase the number of
mutations. Thus, it can be adjusted to our evolving understanding
of the etiology of hearing loss and may be more clinically useful in
a future configuration.
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